Lacosamide for Seizure Prophylaxis in High-Grade Gliomas
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01432171 |
Recruitment Status
:
Active, not recruiting
First Posted
: September 12, 2011
Last Update Posted
: May 26, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The goal of this clinical research study is to learn if an antiepileptic (anti-seizure) treatment will prevent seizures in patients with brain tumors who have not yet had a seizure. Anti-seizure drugs are designed to decrease abnormal electrical activity in the brain that plays a role in developing seizures.
In this study, lacosamide will be used as an anti-seizure medication. Lacosamide will be compared to a placebo.
A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brain Cancer | Drug: Lacosamide Other: Placebo | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 302 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients With High-Grade Gliomas |
Study Start Date : | July 2012 |
Estimated Primary Completion Date : | July 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Lacosamide
Lacosamide or placebo will be taken by mouth twice a day, at approximately the same time each day, spaced as close to 12 hours apart as possible. The starting dose of lacosamide or placebo will be 50 mg PO bid. Over 4 weeks, the dose should be increased to a target dose of 200 mg bid. A recommended scheme for dose escalation is to increase by 100 mg/day weekly until 200 mg bid is achieved.
|
Drug: Lacosamide
Starting dose: 50 mg by mouth twice a day.
Other Name: Vimpat
|
Placebo Comparator: Placebo
Lacosamide or placebo will be taken by mouth twice a day, at approximately the same time each day, spaced as close to 12 hours apart as possible. The starting dose of lacosamide or placebo will be 50 mg PO bid. Over 4 weeks, the dose should be increased to a target dose of 200 mg bid. A recommended scheme for dose escalation is to increase by 100 mg/day weekly until 200 mg bid is achieved.
|
Other: Placebo
To be taken by mouth twice daily.
Other Name: sugar pill
|
- Time to First Seizure (TFS) [ Time Frame: 1 month ]The primary measure of efficacy is time to first seizure (TFS). The primary test of the difference in TFS between the treatment arms based on the likelihood ratio statistic for the treatment effect in a stratified proportional hazards regression model with anticonvulsant use as the stratification factor. The conditional power for the time-to-event outcome computed based on the method described in Design and Analysis of Clinical Trials with Time-to-Event Endpoints and Lan Simon and Halperin.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with histologically confirmed supratentorial high-grade glioma will be eligible for this protocol.
- All patients must sign an informed consent indicating that they are aware of the investigational nature of this study.
- Patients must have signed an authorization for the release of their protected health information.
- Patients must be >/= 18 years old.
- Patients must have a Karnofsky performance status of >/= 60.
- Women of childbearing potential must have a negative beta-HCG pregnancy test documented within 2 weeks prior to registration.
- In the opinion of the treating investigator, patients must have adequate cognitive abilities to complete the neurocognitive components of the study.
- Patients must be able to safely swallow pills.
- Patients must agree to practice adequate contraception.
- Patients must be registered on study within 16 weeks after the surgical procedure that established the diagnosis of High Grade Glioma.
Exclusion Criteria:
- Patients must not have any significant medical or psychiatric illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy.
- Patients must not have serious intercurrent medical illness. Serious, active co-morbidity, defined as follows: a) Unstable angina and/or congestive heart failure requiring hospitalization within the last 12 months. b) Transmural myocardial infarction within the last 6 months. c) Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration. d) Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration. e) Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol.
- (2. continued) f) Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. g) Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity.
- Patients must not be pregnant or breast feeding. Patients must not be pregnant because lacosamide produced developmental toxicity in rats following administration during pregnancy. There is insufficient information to determine if lacosamide is safe during lactation.
- Patients must not have any disease that will obscure toxicity or dangerously alter Drug metabolism
- Patients must not have a history of heart block or cardiac arrhythmia, including asymptomatic arrhythmias and atrial fibrillation/flutter.
- Patients must not have a prolonged PR interval (defined as > 200 ms).
- Perioperative anticonvulsants should be tapered as indicated in the protocol.
- Patients must not have a history of any type of seizure for at least 10 years prior to registration.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01432171
United States, Illinois | |
Northwestern University | |
Chicago, Illinois, United States, 60208 | |
Rush University Medical Center | |
Chicago, Illinois, United States, 60612 | |
Northshore University Health System | |
Evanston, Illinois, United States, 60201 | |
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 | |
United States, Michigan | |
Henry Ford Health System | |
Detroit, Michigan, United States, 48202-2608 | |
United States, Ohio | |
Case Western Reserve University | |
Cleveland, Ohio, United States, 44106 | |
Cleveland Clinic Foundation | |
Cleveland, Ohio, United States, 44195 | |
Ohio State University | |
Columbus, Ohio, United States, 43210 | |
United States, South Carolina | |
Medical University of South Carolina | |
Charleston, South Carolina, United States, 29403 | |
United States, Texas | |
Baylor University Medical Center | |
Dallas, Texas, United States, 75246 | |
UT Southwestern Medical Center at Dallas | |
Dallas, Texas, United States, 75390 | |
University of Texas MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
United States, Wisconsin | |
Aurora Health Care | |
Milwaukee, Wisconsin, United States, 53234 |
Principal Investigator: | Marta Penas-Prado, MD | M.D. Anderson Cancer Center |
Additional Information:
Responsible Party: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT01432171 History of Changes |
Other Study ID Numbers: |
BTTC11-01 NCI-2011-03055 ( Registry Identifier: NCI CTRP ) |
First Posted: | September 12, 2011 Key Record Dates |
Last Update Posted: | May 26, 2016 |
Last Verified: | May 2016 |
Keywords provided by M.D. Anderson Cancer Center:
Brain cancer Central nervous system Seizure prophylaxis High-Grade Gliomas HGG Supratentorial high-grade glioma |
Malignant glioma Lacosamide Vimpat Placebo Sugar pill |
Additional relevant MeSH terms:
Glioma Seizures Brain Neoplasms Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Epilepsy |
Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Signs and Symptoms Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Lacosamide Anticonvulsants |